| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥57.24 |
| 52 Week High | CN¥93.00 |
| 52 Week Low | CN¥48.60 |
| Beta | -0.93 |
| 1 Month Change | 3.60% |
| 3 Month Change | -5.37% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688091 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.0% | 0.3% | -1.8% |
| 1Y | n/a | 0.2% | -5.2% |
Return vs Industry: Insufficient data to determine how 688091 performed against the CN Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 688091 performed against the CN Market.
Price Volatility
| 688091 volatility | |
|---|---|
| 688091 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in CN Market | 8.3% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 688091 is more volatile than 75% of CN stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 688091's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 243 | Jingsong Zhou | https://www.yizhongpharma.com |
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It develops a dosage form of paclitaxel, an anti-tumor chemotherapeutic. Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary
| 688091 fundamental statistics | |
|---|---|
| Market Cap | CN¥9.06b |
| Earnings (TTM) | CN¥169.31m |
| Revenue (TTM) | CN¥348.83m |
53.5x
P/E Ratio26.0x
P/S RatioIs 688091 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688091 income statement (TTM) | |
|---|---|
| Revenue | CN¥348.83m |
| Cost of Revenue | CN¥24.09m |
| Gross Profit | CN¥324.75m |
| Other Expenses | CN¥155.43m |
| Earnings | CN¥169.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.07 |
| Gross Margin | 93.09% |
| Net Profit Margin | 48.54% |
| Debt/Equity Ratio | 1.4% |
How did 688091 perform over the long term?
See historical performance and comparison